Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
Postoperative nausea and vomiting (PONV) is unpleasant and increases health care costs.
Despite modern techniques and prophylaxis, PONV rates remain high after laparoscopic
bariatric surgery. We aim to reduce PONV after laparoscopic bariatric surgery using
aprepitant with a similar scheme used for emetogenic chemotherapy.